VENCLYXTO® (venetoclax tablets)

Dosing Guide

VENCLYXTO SmPC/Country-specific labeling

Contact us

VENCLYXTO® offers patients with CLL a chance to

BREAK FREE with longer progression-free survival¹*^†

NOW APPROVED in 1L CLL: VENCLYXTO + obinutuzumab

In 2L+ CLL:
VENCLYXTO + rituximab

*Reduced risk of progression or death vs O+Clb (HR=0.35; 95% CI: 0.23–0.53 [P<0.0001]). Median follow‑up of 28 months. Median PFS not reached in either arm.

^†Reduced risk of progression or death vs BR (HR=0.17; 95% CI: 0.11–0.25 [P<0.0001]). Median follow‑up of 23.8 months. Median PFS not reached with VEN+R vs 17 months (15.5–21.6) with BR.

Contact us

Please complete the form below and a member of the VENCLYXTO team will get back to you.

Please fill in your details below only if you are a [CountryName] registered healthcare professional and would like to request a meeting with an AbbVie representative.

First name*:

Please enter First name

Last name*:

Please enter Last name

Email address*:

Hospital name*:

Please enter Hospital name

Hospital postcode*:

Please enter Hospital postcode

request

Request a meeting with your local AbbVie representative

Receive email communication from AbbVie. By ticking this box and filling in your email address, you confirm that you are giving permission to receive ongoing electronic communications from AbbVie Ltd. These email communications may include medical, scientific or promotional content on AbbVie’s products and service

Please select one field.

Please note that there may be certain circumstances where we contact you in relation to important AbbVie product or information which we are required to provide to you or your patients as a matter of law, or in order to comply with the obligations we owe to you or them. This type of communication does not constitute as promotional communication.

You can withdraw your consent at any time by using the unsubscribe option in the email or contacting privacyoffice@abbvie.com. For further information about AbbVie’s privacy practices, please refer to the AbbVie Privacy notice.

*Denotes mandatory field.

CLL=chronic lymphocytic leukemia; 1L=first line; 2L+=second line + later lines of therapy; O+Clb=obinutuzumab + chlorambucil; HR=hazard ratio; CI=confidence interval; PFS=progression-free survival; BR=bendamustine + rituximab; VEN+R=VENCLYXTO + rituximab.

[Placeholder for safety balance required by local regulations]

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

I want to find out more about VENCLYXTO

Explore resources

I want to see the product information

Visit the homepage

GR-VNCCLL-200048 -JAN2021

VENCLYXTO (venetoclax) PRESCRIBING INFORMATION/SmPC

I want to find out more about VENCLYXTO

I want to see the product information

This website is intended for Healthcare Professionals only.

Our therapy areas

Additional info